FORT WORTH, TX — January 23, 2026 — Leads & Copy — Sanara MedTech Inc. (Nasdaq: SMTI) has released unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2025, and introduced its financial guidance for the full year ending December 31, 2026.
Net revenue for the fourth quarter of 2025 is expected to be in the range of $27.2 million to $27.7 million, representing an increase of approximately 3% to 5% compared to $26.3 million in the fourth quarter of 2024.
Excluding approximately $1.8 million of BIASURGE® Advanced Surgical Solution (“BIASURGE”) sales in the fourth quarter of 2024 due to industry-wide supply chain issues related to Hurricane Helene, net revenue in the fourth quarter of 2025 is expected to increase approximately 11% to 13% year-over-year.
Net revenue for the full year 2025 is projected to be between $102.7 million and $103.2 million, an increase of approximately 19% compared to $86.7 million for the full year 2024.
Excluding the $1.8 million in BIASURGE sales in the fourth quarter of 2024, net revenue for the full year 2025 is expected to increase approximately 21% to 22% year-over-year.
As of December 31, 2025, Sanara MedTech had approximately $16.6 million in cash and $46.0 million in long-term debt, compared to $15.9 million in cash and $30.7 million in long-term debt as of December 31, 2024.
On December 10, 2025, Sanara provided an update on its strategic alliance with Biomimetic Innovations Ltd (“BMI”) and reaffirmed plans to introduce the OsStic™ Synthetic Injectable Structural Bio-Adhesive (“OsStic”) to the U.S. commercial market in the first quarter of 2027, pending anticipated FDA clearance, to support the treatment of peri-articular fractures.
On January 07, 2026, the company announced its BIASURGE product received an Innovative Technology contract from Vizient, Inc. The contract offers Vizient’s healthcare facility customers access to BIASURGE at contracted pricing and pre-negotiated terms, effective January 1, 2026.
Sanara MedTech expects full-year 2026 net revenue to range from $116 million to $121 million, representing growth of approximately 13% to 17% compared to the midpoint of the expected net revenue range for the full year 2025.
According to Seth Yon, Sanara’s President and Chief Executive Officer, the company delivered strong performance in 2025, with preliminary net revenue of approximately $103 million, an increase of approximately 19% year-over-year. Yon also noted that the company secured a new contract with Vizient, Inc. and is working to expand its product portfolio through initiatives with BMI related to OsStic.
Looking ahead to 2026, Yon expects to deliver net revenue growth of approximately 13% to 17% year-over-year, fueled primarily by sales of its soft tissue products.
Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. The company develops, markets, and distributes surgical products for use by physicians and clinicians in hospitals.
The company’s independent registered public accounting firm has not completed its procedures with respect to the preliminary financial information or its audit of financial statements for the year ended December 31, 2025. Actual results may differ from these estimates as a result of the completion of the audit and other developments that may arise between now and the time financial results for the fourth quarter and fiscal year are finalized.
Source: Sanara MedTech Inc.
